Multiomic Market

How big is Multiomic Market in 2026?

The multiomic market demonstrated steady progress from USD 37.5 billion in 2025 to USD 39.1 billion in 2026, building toward a targeted valuation of USD 60.1 billion by 2036 at a CAGR of 4.4%.

Translational oncology trial sponsors are purchasing multiple molecular assay layers per patient biopsy rather than relying on standalone gene panels to prevent late-stage clinical trial attrition. The global multiomic market was valued at USD 37.5 billion in 2025 and reached USD 39.1 billion in 2026. Total industry valuation is projected by FMI to reach USD 60.1 billion by 2036, expanding at a compound annual growth rate (CAGR) of 4.4% from 2026 to 2036. Genomics and transcriptomics integrated profiles hold an estimated 35.3% share of 2026 modality demand because co-extracting DNA mutations and mRNA transcripts from scarce needle biopsies doubles biomarker hit rates without requiring second patient procedures. That multi-layer reagent pull differentiates the sector from standalone transcriptomics sequencing platforms expanding at a 10.9% CAGR, where orders track single-assay discovery rather than enterprise multi-modal platform contracts. Clinical adoption is reinforced by nationwide trial networks, as the SCRUM-Japan MONSTAR3 platform activated prospective multi-omics profiling across 400 hematologic malignancy patients in November 2025. Instrument suppliers are scaling hardware throughput to capture these recurring kit orders, with Thermo Fisher Scientific unveiling next-generation Orbitrap mass spectrometry systems at ASMS in May 2026 for high-speed multiomic discovery. Cross-platform bioinformatics normalization costs and cold-chain reagent stability nevertheless govern contract conversion across hospital laboratories through 2036.

Key Market Trends & Insights

• By integrated omics modality: Genomics and Transcriptomics Integrated Profiles capture an estimated 35.3% share in 2026 because unified nucleic-acid extraction kits allow simultaneous mutation and gene-expression readout from formalin-fixed biopsies.
• By technology platform: High-Throughput Next-Generation Sequencing Platforms represent 47.4% in 2026 as high-density patterned flow cells process DNA and RNA with oligo-tagged antibodies in one automated run.
• By application domain: Oncology Biomarker Discovery and Patient Stratification accounts for 51.1% in 2026 because antibody-drug conjugate and bispecific trials require multi-modal target validation.
• By workflow component: Multiomic Consumables and Assay Reagents command 46.2% in 2026 due to recurring per-sample library preparation and multiplexing cartridge orders.
• By end user: Biopharmaceutical and Biotechnology Companies hold 48.5% in 2026 through multi-year companion biomarker and translational clinical trial agreements.

Regional Highlights

• Top national expansion: South Korea leads national growth projections at a 5.1% CAGR through 2036 under state-backed precision oncology biobanks and tertiary hospital sequencing centers.
• Broader country progression: The United States advances at a 5.0% CAGR ahead of Australia at 4.5% and Japan at 4.4%, while Switzerland tracks at a 4.2% CAGR.

Market Size & Forecast

Table 1: Market Size and Forecast for the Multiomic Market (USD billion and CAGR percentage), 2025 to 2036

Metric	Value
2025 Market Size	USD 37.5 billion
Estimated Market Size in 2026	USD 39.1 billion
Projected Market Size by 2036	USD 60.1 billion
CAGR, 2026 to 2036	4.4%
Added Market Value, 2026 to 2036	USD 21.0 billion

Biopharmaceutical clinical development teams face high Phase II attrition when single-modality genomic screens fail to detect post-translational protein modifications driving therapy resistance. When oncology trial sponsors evaluate solid tumors using DNA sequencing alone, epigenetic silencing and phosphorylation cascades remain invisible during patient stratification. In September 2026, clinical researchers publishing in Frontiers in Oncology demonstrated that plasma multi-omics profiling in advanced breast cancer patients treated with trastuzumab deruxtecan uncovered distinct molecular remodeling signatures predicting progression-free survival. Consequently, translational medicine directors pair high-throughput sequencing with proteomics profiling workflows to qualify composite responder signatures prior to Phase III trial dosing.

Assay Throughput and Biopsy Sample Sizing

Table 2: Biopsy Sample Throughput and Reagent Sizing for the Multiomic Market (USD billion and operational ranges), 2025 to 2036

Metric	2025	2026	2036
Market size (USD billion)	37.5	39.1	60.1
Multi-modal profiled clinical & research samples (million)	14.2 to 15.8	15.0 to 16.6	24.5 to 27.2
Installed high-throughput multiomic analyzers (thousand units)	28.5 to 31.0	30.2 to 32.8	46.0 to 50.5
Average reagent & bioinformatics valuation per sample (USD)	1,420 to 1,680	1,400 to 1,650	1,280 to 1,510

Operational note: Multi-modal sample ranges reflect paired DNA-RNA sequencing and spatial or mass-spectrometry proteomic workflows across clinical and translational laboratories.

Translational pathology cores require automated library preparation and microfluidic partitioning so fragile cellular transcripts do not degrade during multi-step staining. Instrument vendors supply pre-barcoded reagent cartridges for single-cell analysis systems that process thousands of dissociated nuclei per run without manual pipetting drift.

Per Capita & Translational Core Facility Sizing

Table 3: Per Capita and Core Facility Valuation Indicators for the Multiomic Market (USD), 2025 to 2036

Metric	2025	2026	2036
Global population (billion)	8.2	8.3	9.0
Valuation per 1,000 people (USD)	4,573.2	4,710.8	6,677.8
Annual allocation per translational core facility (USD million)	4.1 to 4.6	4.3 to 4.8	6.2 to 6.9
Spatial & single-cell multi-modal assay share (%)	28.0% to 31.0%	30.0% to 33.5%	44.0% to 48.5%

Table 4: Biopharma & Core Lab Allocation Indicators for the Multiomic Market (USD and percentages), 2026

Metric	Value	Institutional Reference Basis
Market size, 2026	USD 39.1 billion	2026 global market valuation baseline
Active translational & clinical multiomic cores	8,600 facilities	Biopharma R&D, academic, and reference pathology centers
Valuation per active facility	USD 4.55 million	Annualized multiomic hardware, reagent, and cloud allocation
Biopharmaceutical & Biotech segment valuation, 2026	USD 19.0 billion	48.5% end-user market allocation

Petabyte-scale sequencing reads paired with high-resolution mass spectra create severe data-storage bottlenecks for hospital molecular boards. Core laboratories deploy cloud-native computational bioinformatics software with interpretable machine-learning alignment to convert multi-layered molecular matrices into standardized pathology reports.

Analyst Perspective

"Biopharmaceutical sponsors no longer purchase sequencing instruments and mass spectrometers as isolated laboratory capital. Instead, they procure validated multi-modal reagent pipelines that cut Phase II biomarker failure rates. Platform suppliers that bundle pre-barcoded DNA-RNA-protein consumables with automated cloud alignment software will lock in multi-year translational trial contracts through 2036."

- Anurag Sharma, Principal Consultant, Future Market Insights.

How is the multiomic market segmented?

The multiomic market is segmented by integrated omics modality, technology platform, application domain, workflow component, and end user. In 2026, Genomics and Transcriptomics Integrated Profiles are projected at 35.3%, High-Throughput Next-Generation Sequencing Platforms at 47.4%, Oncology Biomarker Discovery and Patient Stratification at 51.1%, Multiomic Consumables and Assay Reagents at 46.2%, and Biopharmaceutical and Biotechnology Companies at 48.5%.

By integrated omics modality: Genomics and Transcriptomics Integrated Profiles lead with Proteomics and Phosphoproteomics Characterization. Metabolomics and Lipidomics Profiles operate with Single-Cell Multiomics Multi-Modal Assays.

By technology platform: High-Throughput Next-Generation Sequencing Platforms lead with High-Resolution Orbitrap Q-TOF Mass Spectrometry. Spatial Biology Multiplex Imaging Systems pair with Microfluidic Single-Cell Barcoding Systems.

By application domain: Oncology Biomarker Discovery and Patient Stratification leads with Target Discovery in Autoimmune and Neurodegenerative Diseases. Personalized Precision Medicine Formulations pair with Infectious Disease and Host-Pathogen Profiling.

By workflow component: Multiomic Consumables and Assay Reagents lead with Multiomic Analyzers and Imaging Hardware. Multi-Modal Bioinformatics and Cloud Interpretation Suites pair with Contract Multiomic Profiling Services.

By end user: Biopharmaceutical and Biotechnology Companies lead with Academic and Translational Research Institutes. Clinical Diagnostic and Reference Laboratories pair with Contract Research Organizations.

Why do Genomics and Transcriptomics Integrated Profiles lead the modality category?

Genomics and Transcriptomics Integrated Profiles hold an estimated 35.3% of modality demand in 2026, supported by co-extraction of DNA and RNA from single solid-tumor biopsies.

Table 5: Integrated Omics Modality Share for the Multiomic Market (percentage share), 2026

Integrated Omics Modality	Share (2026)
Genomics and Transcriptomics Integrated Profiles	35.3%
Other Modality Categories Combined	64.7%*
Total	100.0%

*Note: Remaining integrated omics modality categories account for the balance of 2026 global multiomic demand.

Table 6: Modality Leadership and Market Growth for the Multiomic Market (segment and CAGR percentage), 2026 to 2036

Metric	Value
Global CAGR (2026 to 2036)	4.4%
Leading Segment	Genomics and Transcriptomics Integrated Profiles

Simultaneous extraction of genomic somatic variants and transcriptomic splice isoforms from a single nucleic-acid sample eliminates tissue-section bias in solid-tumor profiling. Clinical trial laboratories already equipped with clinical oncology sequencing infrastructure adopt paired DNA-RNA library kits first because those assays run on existing sequencers without requiring separate mass-spectrometry suites.

• Genomics and Transcriptomics Integrated Profiles hold 35.3% of modality market value in 2026 because dual-extraction chemistry halves biopsy tissue consumption per patient.
• In March 2026, investigators publishing in Genome Medicine applied integrated genomic and transcriptomic profiling to advanced small cell lung cancers and identified distinct therapeutic subtypes guiding targeted trial enrollment.

What sustains High-Throughput Next-Generation Sequencing Platforms leadership in technology?

High-Throughput Next-Generation Sequencing Platforms represent 47.4% of the technology platform category in 2026, anchored by universal DNA, RNA, and oligo-proteomic readout capacity.

High-Throughput Next-Generation Sequencing Platforms function as the universal readout engine for genomic and transcriptomic assays as well as oligo-conjugated proteomic barcoding. By converting protein and chromatin binding events into sequenceable DNA tags, biopharma cores consolidate multi-modal readouts onto high-output sequencers paired with spatial omics instrumentation in centralized core facilities.

• High-Throughput Next-Generation Sequencing Platforms represent 47.4% of the technology platform category in 2026 as oligonucleotide-barcoded antibodies convert proteomic detection into sequencing reads.
• Illumina unveiled its spatial transcriptomics and multiomic roadmap technologies in February 2025 to enable high-resolution cellular mapping directly on high-throughput sequencing flow cells.

How does Oncology Biomarker Discovery and Patient Stratification lead application demand?

Oncology Biomarker Discovery and Patient Stratification accounts for 51.1% of application demand in 2026, driven by targeted ADC and immunotherapy clinical trials.

Oncology drug developers face strict regulatory requirements to demonstrate target expression and resistance mechanisms across heterogeneous tumor microenvironments before launching Phase III trials. Single-cell RNA profiles paired with spatial receptor density enable clinical teams to select high-responder cohorts and link multi-modal assays with next-generation cancer diagnostics for longitudinal monitoring.

• Oncology Biomarker Discovery and Patient Stratification accounts for 51.1% of application demand in 2026 because antibody-drug conjugate and immunotherapy trials require multi-layer tumor microenvironment mapping.
• A September 2026 study in Frontiers in Oncology documented that combining single-cell and spatial multi-omics resolves therapy-resistant cellular niches across solid tumors.

Why do Multiomic Consumables and Assay Reagents lead workflow components?

Multiomic Consumables and Assay Reagents secure 46.2% of workflow component value in 2026, supported by recurring per-biopsy kit utilization.

While multiomic analyzers represent one-time capital installations, high-volume clinical studies consume pre-plated barcoding reagents and mass-spectrometry labeling kits on every patient sample. Standardized consumable cartridges lock translational laboratories into proprietary supplier ecosystems and generate predictable recurring orders across multi-year cohort studies.

• Multiomic Consumables and Assay Reagents secure 46.2% of workflow component valuation in 2026 due to repeat per-biopsy kit utilization across longitudinal trials.
• In June 2025, researchers in Molecular and Cellular Proteomics validated label-free single-cell proteomics consumables on high-resolution Orbitrap analyzers across 100 picogram to 5 nanogram sample loads.

What gives Biopharmaceutical and Biotechnology Companies the leading end-user position?

Biopharmaceutical and Biotechnology Companies command 48.5% of end-user share in 2026, anchored by enterprise translational biomarker pipelines.

Global pharmaceutical companies fund multi-thousand-patient multiomic biomarker screens across Phase I through Phase III pipelines to rescue stalled drug candidates and expand label indications. Unlike academic grants tied to annual budget cycles, biopharma R&D procurement teams sign enterprise master service agreements covering instruments and bioinformatics pipelines.

• Biopharmaceutical and Biotechnology Companies command 48.5% of end-user market size in 2026 because commercial drug pipelines embed multiomic stratification across clinical development.
• In April 2026, Pfizer Inc. presented biomarker-stratified Phase III TALAPRO-3 and HER2CLIMB-05 oncology outcomes demonstrating how genomic repair profiling guides first-line maintenance therapy.

What are the drivers, restraints, and opportunities in the multiomic market?

In the multiomic market, precision oncology biomarker stratification and spatial single-cell barcoding drive adoption whereas cross-platform bioinformatics complexity restrains community lab uptake and plasma liquid multiomics unlocks serial treatment monitoring.

• Driver: Rising clinical adoption of antibody-drug conjugates and cell therapies compels drug sponsors to assay nucleic acids and surface proteins simultaneously on patient biopsies.
• Restraint: High per-sample reagent costs and fragmented cross-platform bioinformatics pipelines delay routine adoption across community hospital pathology laboratories.
• Opportunity: Combining spatial tissue imaging with ultra-sensitive single-cell mass spectrometry unlocks deep biomarker discovery in autoimmune and neurodegenerative disease cohorts.

Growth Analysis and Future Potential: Qualitative Demand Catalysts

Oncology and immunology clinical trial sponsors are shifting procurement from single-analyte PCR tests toward multi-modal profiling to capture post-transcriptional pathway activation. When tumor cells develop resistance to targeted kinase inhibitors without acquiring new DNA mutations, phosphoproteomic and metabolomic assays reveal the bypass signaling cascades driving relapse. Multi-modal workflows connected with oncology tumor profiling allow drug developers to stratify patients by functional pathway activity rather than static mutation status. In October 2026, oncology researchers publishing in Cancer Science demonstrated that integrated transcriptomic and metabolomic profiling in triple-negative breast cancer identified branched-chain amino acid reprogramming linked directly to metastatic progression.

Risk Assessment of the Multiomic Market: Operational and Formulation Friction

Batch-to-batch technical variation between sequencing reads and mass-spectrometry peak intensities remains the primary operational hurdle restricting multiomic assays in regulated clinical diagnostics. Nucleic-acid amplification paired with protein mass spectrometry requires complex statistical batch correction and terabyte-scale cloud computing that strains hospital IT budgets. In July 2026, translational scientists writing in Human Genomics reported that cross-modality data heterogeneity and variant-of-uncertain-significance interpretation gaps continue to slow clinical validation in inherited neuromuscular diseases. Laboratories deploying clinical sequencing data analytics consequently mandate locked algorithmic pipelines and reference standards before moving multi-modal panels into clinical reporting.

Commercial Opportunity Analysis: Formulation Differentiation and Value-Add Formats

Platform vendors unlock high-margin growth by engineering non-invasive plasma multiomic workflows that combine circulating cell-free DNA methylation with high-throughput plasma proteomics. Liquid-based multi-modal assays eliminate surgical tissue biopsy risks and allow serial blood sampling at every chemotherapy cycle to detect minimal residual disease months before radiographic progression. Plasma proteomic panels integrated with circulating liquid biopsy assays expand addressable testing volume across early cancer screening and autoimmune flare monitoring. In August 2026, hepatology investigators in Frontiers in Immunology showed that integrated plasma metabolomics and proteomics accurately tracked dysregulated amino acid pathways driving hepatocellular carcinoma metastasis.

Multiomic Market by Country (2026 to 2036)

FMI country modeling indicates that South Korea leads multiomic market expansion at a 5.1% CAGR through 2036, while the United States tracks at 5.0% and Australia at 4.5% ahead of Switzerland at 4.2%.

Table 7: Country CAGR and Primary Growth Levers for the Multiomic Market (CAGR percentage and operational drivers), 2026 to 2036

Country	CAGR (2026 to 2036)	Primary Growth Lever
South Korea	5.1%	Tertiary hospital genomic hubs and national precision oncology biobanks
United States	5.0%	Biopharma companion biomarker pipelines and NCI multi-modal consortia
United Kingdom	4.7%	Population biobank proteomic layering and Cambridge biopharma R&D
Australia	4.5%	Fast-track Phase I oncology trials and translational genomics grants
Japan	4.4%	SCRUM-Japan MONSTAR3 oncology network and neurology metabolomics
Germany	4.3%	University hospital molecular pathology cores and spatial proteomics
Switzerland	4.2%	Centralized global biopharma biomarker cores in Basel and Zurich
France	4.1%	France Medecine Genomique platforms and immunology biomarker cohorts

Source: Future Market Insights analysis

South Korea Multiomic Market Outlook (2026 to 2036)

Demand for multiomic platforms in South Korea is projected to expand at a 5.1% CAGR from 2026 to 2036 as tertiary medical centers in Seoul integrate whole-genome sequencing with spatial proteomics across oncology trials. Unlike Western healthcare systems where testing is decentralized across regional clinics, tertiary oncology hospitals in South Korea concentrate high-volume patient cohorts inside university genomic centers that run automated multi-modal library lines. In September 2025, translational immunologists in Frontiers in Immunology demonstrated how integrated single-cell and spatial transcriptomics mapped human papillomavirus immune microenvironments for patient prognosis. National biobanks and cell-therapy exporters in Seoul and Incheon consequently procure high-throughput sequencing and mass-spectrometry consumables under multi-year supply agreements.

Key takeaway: In South Korea, centralized tertiary hospital genomics hubs and national precision oncology biobanks are projected to drive leading 5.1% CAGR multiomic adoption.

United States Multiomic Market Outlook (2026 to 2036)

Valuation of the multiomic market in the United States is forecast to advance at a 5.0% CAGR from 2026 through 2036, supported by pharmaceutical biomarker budgets and National Cancer Institute translational consortia. What distinguishes demand in the United States from other regions is the scale of private biopharma clinical trial sponsorship requiring companion multi-modal assays for antibody-drug conjugates and radioligand therapies. In October 2026, Merck and Co. Inc. and Moderna announced Phase III Interpath-001 melanoma trial presentations highlighting personalized mRNA neoantigen stratification built on tumor sequencing. Reference laboratories and academic medical centers in Boston and Houston continue expanding Orbitrap mass spectrometry and spatial imaging capacity for clinical studies.

Key takeaway: In the United States, biopharma companion biomarker pipelines and personalized neoantigen oncology trials are forecast to sustain 5.0% CAGR expansion.

United Kingdom Multiomic Market Outlook (2026 to 2036)

Multiomic market size in the United Kingdom is anticipated to progress at a 4.7% CAGR through 2036 as population-scale biobanks add proteomic and metabolomic layers onto sequenced participant cohorts. Whereas commercial trial sponsors dominate procurement in North America, demand in the United Kingdom is catalyzed by public-private population genomics partnerships linking NHS clinical records with high-plex plasma proteomics. In October 2026, AstraZeneca plc published its 2025 Annual Report detailing expanded multi-omic biomarker integration across oncology and rare disease clinical pipelines in Cambridge. Biobank core laboratories across London and Oxford consequently purchase high-throughput library preparation kits and mass-spectrometry reagents for longitudinal cohort profiling across half a million enrolled citizens.

Key takeaway: In the United Kingdom, population biobank proteomic layering and Cambridge biopharma R&D pipelines are anticipated to support 4.7% CAGR growth.

Australia Multiomic Market Outlook (2026 to 2036)

Industry valuation for multiomic platforms in Australia is estimated to grow at a 4.5% CAGR from 2026 to 2036 across translational cancer institutes in Melbourne and Sydney. Australia diverges from larger Northern Hemisphere markets by leveraging fast-track Phase I oncology trial regulations and federal Medical Research Future Fund grants to attract international multi-modal biomarker studies. In May 2025, researchers publishing in Genomics Proteomics and Bioinformatics documented how mass-spectrometry single-cell proteomics workflows resolve cellular heterogeneity in clinical tissue cohorts. Contract research organizations and university genomics nodes in Australia actively invest in spatial transcriptomics imagers and automated single-cell barcoding consumables to service global biopharma sponsors running early-phase solid-tumor trials.

Key takeaway: In Australia, fast-track Phase I oncology trial centers and federal translational genomics grants are estimated to sustain 4.5% CAGR progression.

Japan Multiomic Market Outlook (2026 to 2036)

Multiomic market valuation in Japan is projected to rise at a 4.4% CAGR between 2026 and 2036, driven by nationwide hospital genomic screening networks and aging-population neurodegenerative research. Unlike fragmented laboratory markets, hospital networks in Japan coordinate multi-center specimen collection through National Cancer Center consortia that standardize nucleic-acid and protein extraction protocols across prefectures. In October 2025, neuroscientists writing in Neurotherapeutics applied integrated serum metabolomics and lipidomics to identify biomarker signatures distinguishing Alzheimer disease from mild cognitive impairment. Pharmaceutical manufacturers and clinical core laboratories in Tokyo and Osaka consequently prioritize high-precision Orbitrap mass spectrometers and spatial transcriptomics kits for oncology and neurology biomarker discovery programs.

Key takeaway: In Japan, nationwide cancer hospital screening consortia and neurodegenerative metabolomics programs are projected to maintain a 4.4% CAGR.

Germany Multiomic Market Outlook (2026 to 2036)

Demand for multiomic solutions in Germany is slated to expand at a 4.3% CAGR across the 2026 to 2036 horizon within university hospital pathology departments and industrial biopharma campuses. Germany stands apart within continental Europe through its dense network of translational oncology centers and high-precision analytical instrumentation engineering hubs in Munich and Heidelberg. In August 2026, investigators in EMBO Molecular Medicine introduced Deep Visual Multi-Omics combining digital pathology and single-cell profiling to map molecular programs in renal cell carcinoma. University clinics and pharmaceutical R&D teams across Germany are integrating spatial biology imagers with ultra-sensitive mass spectrometers to validate solid-tumor drug targets and companion diagnostic signatures.

Key takeaway: In Germany, university hospital molecular pathology centers and spatial-proteomic oncology research are slated to drive 4.3% CAGR expansion.

Switzerland Multiomic Market Outlook (2026 to 2036)

Valuation of the multiomic market in Switzerland is forecast to advance at a 4.2% CAGR through 2036, anchored by global pharmaceutical headquarters in Basel and translational institutes in Zurich and Lausanne. Although Switzerland has a smaller domestic patient population than neighboring countries, global clinical trial specimens from multinational immunology and oncology studies are routed into Basel core laboratories for centralized multi-modal biomarker interrogation. In October 2026, Novartis AG presented Phase III REMODEL trial results in relapsing multiple sclerosis supported by comprehensive neuroimaging and biomarker evaluation. Pharmaceutical biomarker cores in Switzerland maintain high per-instrument utilization of single-cell sequencing and spatial proteomics reagents across international trial cohorts.

Key takeaway: In Switzerland, centralized global biopharma biomarker cores in Basel and Zurich are forecast to support steady 4.2% CAGR multiomic demand.

France Multiomic Market Outlook (2026 to 2036)

Multiomic market size in France is predicted to climb at a 4.1% CAGR from 2026 to 2036 across state-funded genomic medicine sequencing centers and Paris biocluster immunology research institutes. Demand in France is shaped by state-funded France Medecine Genomique sequencing hubs and major pharmaceutical investments targeting autoimmune and rare inflammatory pathways. In October 2026, Sanofi SA reported third-quarter 2026 financial results highlighting rapid uptake of specialty immunology and rare blood therapeutics supported by precision biomarker selection. Public oncology institutes and private translational laboratories in Paris and Lyon are expanding paired RNA-protein single-cell assay capacity to stratify patient cohorts for targeted biologics and cellular immunotherapies.

Key takeaway: In France, national genomic medicine sequencing platforms and immunology biomarker programs are predicted to sustain a 4.1% CAGR.

Full report country CAGRs cover: North America and Latin America with Western Europe and Eastern Europe. Coverage also spans East Asia and South Asia and Pacific with Middle East and Africa.

Who are the notable companies in the multiomic market?

Pfizer Inc., Novartis AG, Roche Holding AG, Merck and Co. Inc., Sanofi SA, Thermo Fisher Scientific Inc., Danaher Corporation, Illumina Inc., 10x Genomics Inc., and Bruker Corporation are the notable companies in the multiomic market.

Competitive positioning in the multiomic industry connects biopharmaceutical translational sponsors that deploy multi-modal biomarker pipelines with analytical instrumentation and reagent manufacturers. Pfizer Inc. and Novartis AG with Roche Holding AG lead clinical biomarker deployment and diagnostic integration. Merck and Co. Inc. and Sanofi SA advance immuno-oncology and autoimmune multiomic stratification. Thermo Fisher Scientific Inc. and Danaher Corporation with Illumina Inc. and Bruker Corporation supply core sequencing and spatial biology platforms.

• Biopharmaceutical Translational and Diagnostic Leaders: Pfizer Inc. and Novartis AG operate with Roche Holding AG and Merck and Co. Inc. as well as Sanofi SA to integrate multi-modal genomic and proteomic biomarker assays across oncology trials.
• Core Sequencing and Mass Spectrometry Platform Manufacturers: Thermo Fisher Scientific Inc. and Danaher Corporation with Illumina Inc. manufacture high-throughput next-generation sequencers and Orbitrap mass spectrometers with automated sample-preparation consumables.
• Spatial Biology and Single-Cell Multiomic Specialists: 10x Genomics Inc. and Bruker Corporation engineer microfluidic single-cell barcoding systems and high-plex spatial proteomics analyzers for intact tissue sections.

Competitive Benchmarking: Multiomic Market

Table 8: Competitive Benchmarking for the Multiomic Market (qualitative capability ratings), 2026

Company	Multi-Modal Assay Integration	Translational Pipeline Reach	Bioinformatics & Spatial Fit	Geographic Reach
Pfizer Inc.	High	High	High	Global oncology biomarker deployment across Phase III ADC and combination trials
Novartis AG	High	High	High	Basel and global translational biomarker cores across neuroscience and oncology
Roche Holding AG	High	High	High	Global pharmaceuticals and diagnostics network; ESMO 2026 biomarker programs
Merck and Co. Inc.	High	High	High	Global immuno-oncology neoantigen and companion diagnostic trial footprint
Sanofi SA	Medium	High	High	Global immunology and rare disease translational biomarker stratification
Thermo Fisher Scientific Inc.	High	High	High	Global Orbitrap Astral Zoom MS and Ion Torrent sequencing installations
Danaher Corporation	High	High	High	Global life sciences mass spectrometry, flow cytometry, and diagnostics network
Illumina Inc.	High	High	High	Global NovaSeq X sequencing fleet and spatial transcriptomics workflow
10x Genomics Inc.	High	Medium	High	North America, Europe, and Asia-Pacific Chromium single-cell and Xenium spatial hubs
Bruker Corporation	High	Medium	High	Global timsTOF mass spectrometry and CellScape XR spatial proteomics network

Evaluation basis: Multi-Modal Assay Integration evaluates documented capability to link nucleic-acid and proteomic layers on clinical samples, whereas Translational Pipeline Reach rates global trial deployment and core-lab installed base. Bioinformatics & Spatial Fit measures cloud multi-omics alignment and spatial tissue resolution.

Key Developments in the Multiomic Market

• Roche Holding AG presented Phase III oncology and exploratory biomarker data across its lung and breast cancer portfolio at ESMO in October 2026.
• Bruker Corporation launched the CellScape XR spatial proteomics platform in February 2026 to accelerate diagnostic and prognostic spatial multiomics in translational pathology.
• Danaher Corporation reported 8.5% year-over-year third-quarter growth in October 2026 driven by life sciences bioprocessing and molecular diagnostics consumables demand.

Key Players in the Multiomic Market

Biopharmaceutical Translational and Diagnostic Leaders

• Pfizer Inc.
• Novartis AG
• Roche Holding AG
• Merck and Co. Inc.

Core Sequencing and Mass Spectrometry Platform Manufacturers

• Sanofi SA
• Thermo Fisher Scientific Inc.
• Danaher Corporation
• Illumina Inc.

Spatial Biology and Single-Cell Multiomic Specialists

• 10x Genomics Inc.
• Bruker Corporation

Multiomic Market - Report Scope

Table 9: Report Scope for the Multiomic Market (coverage fields and definitions), 2026 to 2036

Coverage field	Report scope
Market breakdown	Integrated Omics Modality; Technology Platform; Application Domain; Workflow Component; End User
Quantitative Units	USD Billion
Market Definition	Encompasses commercial valuation from multi-modal analyzers, sequencing and mass-spectrometry consumables, spatial imaging kits, and bioinformatics platforms used to integrate two or more molecular layers (genomics, transcriptomics, proteomics, metabolomics, lipidomics, epigenomics). Category Scope Note: Excludes standalone single-gene PCR tests and routine single-analyte clinical chemistry panels.
Regions Covered	North America; Latin America; Western Europe; Eastern Europe; East Asia; South Asia and Pacific; Middle East and Africa
Countries Covered	South Korea, United States, United Kingdom, Australia, Japan, Germany, Switzerland, France, and additional countries in the full report
Key Companies Covered	Pfizer Inc., Novartis AG, Roche Holding AG, Merck and Co. Inc., Sanofi SA, Thermo Fisher Scientific Inc., Danaher Corporation, Illumina Inc., 10x Genomics Inc., Bruker Corporation
Forecast Period	2026 to 2036
Approach	Primary and secondary research with top-down and bottom-up market triangulation. Child market represents 3.3% of Global Pharmaceutical and Medical Technology Industry.

Multiomic Market - Research Methodology

Table 10: Research Methodology for the Multiomic Market (research methods and approach), 2026 edition

Method	Approach
Primary Research	Structured interviews with biopharmaceutical translational oncology directors, hospital molecular pathology heads, mass-spectrometry core managers, and spatial biology bioinformatics architects.
Secondary Research	Analysis of peer-reviewed multi-omics clinical studies in PubMed and EuropePMC, SEC Form 10-K and 20-F corporate filings, and national biobank registries.
Market Sizing and Forecasting	Valuation triangulated via physical volume shipments, manufacturer ASP realizations, and published industry reports. Child market represents 3.3% of Global Pharmaceutical and Medical Technology Industry.
Country Forecasting Model	Econometric projections weight national precision-medicine sequencing budgets, Phase I to III oncology trial site density, and biobank multi-modal cohort expansion across eight national markets.
Operational Benchmark Traceability	Biopsy throughput and core facility indicators in Tables 2, 3, and 4 trace to prospective multi-omics clinical trial registries and instrument throughput specifications.
Data Triangulation and Validation	Compounding validated at 4.4% CAGR from USD 39.1 billion in 2026 to USD 60.1 billion by 2036 with zero hierarchy anomalies.

Multiomic Market by Segments

Multiomic Market segmented by Integrated Omics Modality:

• Genomics and Transcriptomics Integrated Profiles
• Proteomics and Phosphoproteomics Characterization
• Metabolomics and Lipidomics Profiles
• Single-Cell Multiomics Multi-Modal Assays

Multiomic Market segmented by Technology Platform:

• High-Throughput Next-Generation Sequencing Platforms
• High-Resolution Orbitrap Q-TOF Mass Spectrometry
• Spatial Biology Multiplex Imaging Systems
• Microfluidic Single-Cell Barcoding Systems

Multiomic Market segmented by Application Domain:

• Oncology Biomarker Discovery and Patient Stratification
• Target Discovery in Autoimmune and Neurodegenerative Diseases
• Personalized Precision Medicine Formulations
• Infectious Disease and Host-Pathogen Profiling
• Metabolic and Cardiovascular Risk Profiling

Multiomic Market segmented by Workflow Component:

• Multiomic Consumables and Assay Reagents
• Multiomic Analyzers and Imaging Hardware
• Multi-Modal Bioinformatics and Cloud Interpretation Suites
• Contract Multiomic Profiling Services

Multiomic Market segmented by End User:

• Biopharmaceutical and Biotechnology Companies
• Academic and Translational Research Institutes
• Clinical Diagnostic and Reference Laboratories
• Contract Research Organizations

Multiomic Market by Region

• North America
  • United States
  • Canada
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Chile
• Western Europe
  • Germany
  • France
  • United Kingdom
  • Switzerland
  • Italy
  • Spain
  • Benelux
• Eastern Europe
  • Poland
  • Czech Republic
  • Romania
  • Hungary
• East Asia
  • China
  • Japan
  • South Korea
• South Asia and Pacific
  • India
  • ASEAN
  • Australia
• Middle East and Africa
  • GCC Countries
  • South Africa
  • Türkiye
  • Israel

Research Sources and Bibliography

• [1] Minami, Y. & National Cancer Center Japan MONSTAR3 Investigators. (2026, July 15). SCRUM-Japan MONSTAR3 hematology cohort: a nationwide multi-omics integrated platform for next-generation precision medicine in hematologic malignancies. International Journal of Clinical Oncology, 31(7), 1108 to 1116 (PubMed PMID 42177352).
• [2] Thermo Fisher Scientific Inc. (2026, May 28). Thermo Fisher Scientific Unveils Next-Generation Innovations at ASMS 2026 to Accelerate the Path from Drug Discovery to New Therapies. Thermo Fisher Scientific Investor Relations.
• [3] Wang, L. & Breast Oncology Translational Consortium. (2026, September 18). Plasma multi-omics reveals molecular remodeling and prognostic biomarkers in advanced breast cancer treated with trastuzumab deruxtecan. Frontiers in Oncology, 16, 1973097 (PubMed PMID 42827766).
• [4] Zhang, Y. & Precision Oncology Working Group. (2025, November 21). Multi-omics strategies for biomarker discovery and application in personalized oncology. Molecular Cancer, 24, 289 (PubMed PMID 41269529).
• [5] Chen, M. & Single-Cell Atlas Consortium. (2026, January 9). Single cell multi-omics atlases unlock cellular mysteries. Briefings in Bioinformatics, 27(1), bbaf612 (PubMed PMID 41519642).
• [6] Li, K. & Computational Oncology Group. (2026, August 31). Multi-Omics-Driven Insights into Cancer Biology and Therapeutic Target Discovery. Cancers, 18(17), 2641 (PubMed PMID 42675339).
• [7] Simpson, K. L. & QIMR Berghofer Lung Cancer Investigators. (2026, March 17). Multi-omics reveals key molecular and cellular features of advanced small cell lung cancers associated with distinct therapeutic opportunities. Genome Medicine, 18(1), 47 (PubMed PMID 41845530).
• [8] Illumina Inc. (2025, February 19). Illumina unveils first-of-its-kind spatial transcriptomics technology. Illumina Corporate News Center.
• [9] Gomez, A. & Spatial Oncology Network. (2026, September 14). Clinical Assessment: Integrating single-cell and spatial multi-omics for precision oncology. Frontiers in Oncology, 16, 1944210 (PubMed PMID 42807768).
• [10] Bubis, J. A. & Orbitrap Single-Cell Proteomics Group. (2025, June 15). Quantitative Label-Free Single-Cell Proteomics on the Orbitrap Astral Mass Spectrometer. Molecular and Cellular Proteomics, 24(6), 100982 (PubMed PMID 40334743).
• [11] Pfizer Inc. (2026, April 21). Pfizer Showcases Oncology Innovation and Next-Generation Pipeline Advances. Pfizer Media Relations.
• [12] Tanaka, H. & Breast Metabolism Study Group. (2026, October 11). Multi-Omics Integration Reveals Metabolic Reprogramming and EMT-Driven Metastasis in Triple-Negative Breast Cancer. Cancer Science, 117(11), 70559 (PubMed PMID 42860598).
• [13] Zhou, W. & Inherited Neuromuscular Translational Consortium. (2026, July 21). Multi-omics Integration in Inherited Neuromuscular Diseases. Human Genomics, 20(1), 88 (PubMed PMID 42483609).
• [14] Liu, J. & Hepatobiliary Multi-Omics Group. (2026, August 19). Integrated multi-omics analysis of metabolomics and proteomics uncovers dysregulated amino acid metabolism in HCC metastasis. Frontiers in Immunology, 17, 1856643 (PubMed PMID 42688489).
• [15] Park, S. & Cervical Cancer Spatial Omics Investigators. (2025, September 16). Integrated multi-omics analysis of single-cell and spatial transcriptomics reveals distinct HPV-associated immune microenvironment features and prognostic signatures in cervical cancer. Frontiers in Immunology, 16, 1612401 (PubMed PMID 41035636).
• [16] Merck and Co Inc. (2026, October 22). Merck and Moderna Will Present Results From Landmark Phase 3 Interpath-001 Trial for Intismeran Autogene Plus Keytruda at ESMO 2026 Presidential Symposium. Merck Corporate Newsroom.
• [17] AstraZeneca plc. (2026, October 19). AstraZeneca Annual Report and Form 20-F Information 2025. AstraZeneca Investor Relations.
• [18] Sun, Y. & Single-Cell Mass Spectrometry Consortium. (2025, May 10). Mass Spectrometry-based Solutions for Single-cell Proteomics. Genomics Proteomics and Bioinformatics, 23(1), qzaf012 (PubMed PMID 39985441).
• [19] Nakamura, T. & Alzheimer Metabolomics Study Group. (2025, October 15). Metabolomics and lipidomics study on serum metabolite signatures in Alzheimer disease and mild cognitive impairment. Neurotherapeutics, 22(6), e00756 (PubMed PMID 41006122).
• [20] Meier, F. & Renal Pathology Consortium. (2026, August 6). Deep visual multi-omics profiling links morphology and molecular programs in clear cell renal cell carcinoma. EMBO Molecular Medicine, 18(9), 3850 to 3877 (PubMed PMID 42562882).
• [21] Novartis AG. (2026, October 23). Novartis remibrutinib delivered comprehensive disease control in Phase III RMS trials with proven safety profile. Novartis Media Releases.
• [22] Sanofi SA. (2026, October 30). Sanofi Third Quarter 2026 Financial and Pipeline Results. Sanofi Investor Relations.
• [23] Roche Holding AG. (2026, October 18). Roche to present Phase III data at ESMO 2026 advancing lung and breast cancer late-stage portfolio. Roche Media Releases.
• [24] Bruker Corporation. (2026, February 25). Bruker Accelerates the Future of Diagnostic and Prognostic Spatial Proteomics with the Launch of CellScape XR. Bruker Investor Relations.
• [25] Danaher Corporation. (2026, October 21). Danaher Reports Third Quarter 2026 Results. Danaher Investor Relations.
• [26] Zhao, Q. & Spatial Computational Biology Group. (2026, February 18). Interpretable data integration for single-cell and spatial multi-omics. Nature Communications, 17, 1492 (PubMed PMID 41643671).
• [27] Cai, L. & Caltech Division of Biology and Biological Engineering. (2025, May 15). Spatial multi-omics reveals cell-type-specific nuclear compartments. Nature, 641, 712 to 720 (PubMed PMID 40205045).
• [28] Stevens, B. & Cortical Pathology Spatial Consortium. (2026, October 28). Multimodal spatial transcriptomics redefines cortical pathology in Huntington disease. Cell, 189(22), 1210 to 1228 (PubMed PMID 42950818).
• [29] Moehring, T. & Thermo Fisher Scientific Proteomics Applications Team. (2026, October 21). Single-Cell Proteomics with the Orbitrap Astral Zoom Mass Spectrometer. Thermo Fisher Scientific AnalyteGuru Technical Publications.
• [30] Keller, R. & Myeloma Multi-Omics Study Group. (2026, April 22). Mass spectrometry-based proteomics and metabolomics in multiple myeloma risk stratification. Leukemia, 40(5), 982 to 994 (PubMed PMID 42100277).
• [31] Illumina Inc. (2025, February 24). Illumina transforms multiomic research with new technologies spanning genomics, spatial, and single-cell workflows. Illumina Corporate News Center.
• [32] Abbott Laboratories. (2026, October 26). Abbott launches whole-genome sequencing Oncodetect molecular residual disease test to detect traces of cancer during and after treatment. Abbott Corporate MediaRoom.

This reference list supports the primary and secondary analysis presented in this summary.

This Report Answers

• What is the global multiomic market size in 2026 and the forecast valuation for 2036?
• How do biopharma trial biomarker requirements drive multi-modal reagent kit adoption?
• Why do Genomics and Transcriptomics Integrated Profiles lead the modality breakdown?
• Why do High-Throughput Next-Generation Sequencing Platforms lead technology platforms?
• How do country growth rates compare across South Korea and the United States with Australia and Japan?
• How do biopharma translational sponsors interact with sequencing and mass-spectrometry vendors?
• What bioinformatics and sample-prep hurdles restrain routine hospital adoption of multiomics?
• What should clinical laboratories evaluate before investing in spatial and single-cell platforms?